theglobeandmail.comAUG 291 min read$HQY

Healthequity (HQY) Receives a Buy from Barclays

Barclays analyst Peter Warendorf maintained a Buy rating on Healthequity (HQY) with a $110 price target. Bank of America also has a Buy rating with a $125 target. Healthequity reported Q2 revenue of $350.73M and net profit of $65.64M, up from $325.84M and $59.85M last year.

Original reporting

theglobeandmail.com

Published Aug 29, 2026, 8:37 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 29, 2026, 9:08 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Healthequity (HQY) Receives a Buy from Barclays — source image — Source · theglobeandmail.com

Decision brief

The 30-second read

$HQYBullishMed

Why it matters

Analyst upgrades and earnings beat could drive short-term price appreciation.

Market read

Earnings release and analyst upgrades provide a fresh catalyst for HQY.

What to watch

Potential headwinds from reimbursement policy changes.

Relevance 6/10Novelty 7/10Timing: today

Background

Healthequity is a U.S.-listed health benefits platform; recent coverage includes analyst upgrades.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HQYBullishMedium confidence

Context

Barclays maintained a Buy rating on Healthequity and disclosed quarterly revenue of $350.73M and net profit of $65.64M.

Expected impact

Potential upside toward $110 target.

Evidence & confidence

Earnings exceed prior year and analyst raises target, indicating bullish sentiment.

Market effects

Sector

Healthcare benefits from positive earnings and analyst coverage.

Regional

U.S. small-cap healthcare sector may see modest gains.

Global

Limited to U.S. market participants.

Counterpoint

What could challenge this read

The earnings beat may already be priced in; caution on valuation.

Key entities

Analyst
Barclays
Maintained Buy rating and set $110 price target.
Analyst
Bank of America Securities
Maintained Buy rating with $125 price target.

Read at source ← All news

SEP 1

$HQYMedAI 8/10

HealthEquity’s (HQY) Health Savings Engine Hits A New Gear

HealthEquity (HQY) reported Q2 2027 revenue growth of 8% YoY, up from 7%, with adjusted EBITDA rising 11% to $167M. HSA accounts grew 24% YoY to 202K, and total HSA assets reached $37.9B. Management raised full-year guidance, but noted pricing pressure and GAAP net income was $65.6M.

insidermonkey.com3 min

SEP 1

$HQYHighAI 8/10

HealthEquity (HQY) Q2 2027 Earnings Call Transcript

HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.

fool.com3 min

AUG 30

$HQYHighAI 8/10

HealthEquity: Adjusted EBITDA Margin Hits Record 48% As HSA Assets Grow 14% To $37.9 Billion

HealthEquity reported Q2 revenue of $350.7M, up 8% YoY. Adjusted EBITDA rose 11% to $167M, with a record margin of 48%. HSA assets grew 14% to $37.9B. Net income increased 10% to $65.6M. The company raised fiscal 2027 guidance, citing strong execution and operating leverage.

pulse2.com2 min

AUG 30

$HQYMed

Why HealthEquity Stock Sank This Week

HealthEquity (HQY) stock fell 8.6% this week despite beating earnings and revenue estimates for Q2. The company reported adjusted EPS of $1.24 on revenue of $350.7M, up 15.7% and 7.6% YoY, respectively. Investors expected stronger guidance, as the company only slightly raised its full-year revenue target and reiterated EPS guidance.

fool.com2 min

AUG 29

$HQYHigh

HealthEquity (HQY) Stock Rebounds As Record Margins Sharpen The Bull Case

HealthEquity (HQY) stock rose 3.2% to $96.37 after Q2 results showed record adjusted EBITDA margin of 48%, revenue up 7.6% to $350.7M, and net income up 9.7% to $65.6M. Bulls highlight cost reductions and growth in HSA accounts, while bears caution on interest rate risks and pricing pressures. The company raised FY2027 guidance.

simplywall.st2 min

AUG 28